ASCO 2022 Conference Coverage


 

Lecture Summary - ASCO 2022 on the Phase 3 AcceleRET Lung Study: 1L Pralsetinib in RET Fusion+ Advanced/Metastatic NSCLC

27 views
July 14, 2022
Comments 0
Login to view comments. Click here to Login